Crossject
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Crossject is a specialty pharmaceutical company that develops drug-device combinations for emergency medical situations. Its core product is ZENEO®, a proprietary and patented needle-free auto-injector platform. This pre-filled, single-use device is designed for the rapid, safe, and easy administration of life-saving medications by patients or untrained caregivers. The technology propels medication through the skin in less than a tenth of a second. Crossject's product pipeline leverages the ZENEO® platform to address critical conditions such as epileptic seizures, adrenal crisis, and allergic shock, aiming to revolutionize drug delivery in emergency medicine.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-22 07:30 |
Capital/Financing Update
CROSSJECT obtient un financement supplémentaire de la BARDA pour soutenir le dé…
|
French | 89.8 KB | ||
| 2025-09-22 07:30 |
Regulatory News Service
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental an…
|
English | 117.2 KB | ||
| 2025-08-27 17:30 |
Declaration of Voting Results & Voting Rights Announcements
CROSSJECT : Information relative au nombre total de droits de vote et d'actions…
|
French | 132.1 KB | ||
| 2025-08-04 17:35 |
Regulatory News Service
CROSSJECT reste mobilisé pendant la coupure estivale
|
French | 387.7 KB | ||
| 2025-08-04 17:35 |
Regulatory News Service
CROSSJECT remains engaged during the summer break
|
English | 374.9 KB | ||
| 2025-07-08 17:30 |
Capital/Financing Update
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE S1 2025
|
French | 116.1 KB | ||
| 2025-07-01 07:30 |
Delisting Announcement
CROSSJECT annonce la cessation et la mise en œuvre d’un nouveau contrat de liqu…
|
French | 105.6 KB | ||
| 2025-06-24 19:00 |
Share Issue/Capital Change
CROSSJECT annonce le vif succès de son augmentation de capital portée à 5,7 mil…
|
French | 213.9 KB | ||
| 2025-06-24 19:00 |
Share Issue/Capital Change
CROSSJECT announces a successful capital increase of €5.7 million following ful…
|
English | 206.2 KB | ||
| 2025-06-11 07:30 |
Earnings Release
CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les…
|
French | 108.9 KB | ||
| 2025-06-11 07:30 |
Regulatory News Service
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epi…
|
English | 110.5 KB | ||
| 2025-06-06 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 152.9 KB | ||
| 2025-06-04 20:21 |
Share Issue/Capital Change
Lancement d’une augmentation de capital avec maintien du droit préférentiel de …
|
French | 292.3 KB | ||
| 2025-06-04 20:21 |
Share Issue/Capital Change
Launch of a capital increase with preferential subscription rights for nearly …
|
English | 216.7 KB | ||
| 2025-06-03 07:30 |
Investor Presentation
Maxim Group initie la couverture de l'action CROSSJECT avec une note à l’achat …
|
French | 100.9 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
